GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (LTS:0QXH) » Definitions » 3-Year EPS without NRI Growth Rate

Epigenomics AG (LTS:0QXH) 3-Year EPS without NRI Growth Rate : 41.00% (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Epigenomics AG 3-Year EPS without NRI Growth Rate?

Epigenomics AG's EPS without NRI for the three months ended in Jun. 2023 was €-3.17.

During the past 3 years, the average EPS without NRI Growth Rate was 41.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 37.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 22.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Epigenomics AG was 61.20% per year. The lowest was -62.20% per year. And the median was 13.00% per year.


Competitive Comparison of Epigenomics AG's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Epigenomics AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's 3-Year EPS without NRI Growth Rate falls into.



Epigenomics AG 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Epigenomics AG  (LTS:0QXH) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Epigenomics AG 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (LTS:0QXH) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (LTS:0QXH) Headlines

No Headlines